These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18841158)

  • 1. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer.
    Mathew P; Thall PF; Wen S; Bucana C; Jones D; Horne E; Oh WK; Morris MJ; Lee YC; Logothetis CJ; Lin SH; Fidler IJ
    Br J Cancer; 2008 Nov; 99(9):1426-32. PubMed ID: 18841158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
    Mathew P; Thall PF; Bucana CD; Oh WK; Morris MJ; Jones DM; Johnson MM; Wen S; Pagliaro LC; Tannir NM; Tu SM; Meluch AA; Smith L; Cohen L; Kim SJ; Troncoso P; Fidler IJ; Logothetis CJ
    Clin Cancer Res; 2007 Oct; 13(19):5816-24. PubMed ID: 17908974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor.
    Rosenberg A; Mathew P
    Expert Opin Investig Drugs; 2013 Jun; 22(6):787-94. PubMed ID: 23540855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib.
    Mathew P; Tannir N; Tu SM; Wen S; Guo CC; Marcott V; Bekele BN; Pagliaro L
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):889-96. PubMed ID: 21290244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
    J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer.
    Mathew P; Pisters LL; Wood CG; Papadopoulos JN; Williams DL; Thall PF; Wen S; Horne E; Oborn CJ; Langley R; Fidler IJ; Pettaway CA
    J Urol; 2009 Jan; 181(1):81-7; discussion 87. PubMed ID: 19012911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases.
    Mathew P; Wen S; Morita S; Thall PF
    J Interferon Cytokine Res; 2011 Jul; 31(7):539-44. PubMed ID: 21323568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer.
    Mathew P; Fidler IJ; Logothetis CJ
    Semin Oncol; 2004 Apr; 31(2 Suppl 6):24-9. PubMed ID: 15176001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of platelet-derived growth factor signaling in healing myocardial infarcts.
    Zymek P; Bujak M; Chatila K; Cieslak A; Thakker G; Entman ML; Frangogiannis NG
    J Am Coll Cardiol; 2006 Dec; 48(11):2315-23. PubMed ID: 17161265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.
    Yoo C; Kim SB; Ro J; Im SA; Im YH; Kim JH; Ahn JH; Jung KH; Song HS; Kang SY; Park HS; Chung HC
    Cancer Res Treat; 2016 Apr; 48(2):499-507. PubMed ID: 26194374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
    Shawver LK; Schwartz DP; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs JS; Tang C; Ullrich A; Berens ME; Hersh E; McMahon G; Hirth KP; Powell TJ
    Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
    Hofer MD; Fecko A; Shen R; Setlur SR; Pienta KG; Tomlins SA; Chinnaiyan AM; Rubin MA
    Neoplasia; 2004; 6(5):503-12. PubMed ID: 15548358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
    Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
    Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
    Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
    Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
    J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.
    Huang CH; Williamson SK; Van Veldhuizen PJ; Hsueh CT; Allen A; Tawfik O; Wick J; Smith H; Uypeckcuat AM; Mayo M; Kelly K
    J Thorac Oncol; 2011 Feb; 6(2):372-7. PubMed ID: 21178640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
    Yao A; Sejima T; Iwamoto H; Masago T; Morizane S; Honda M; Takenaka A
    Int J Urol; 2015 Sep; 22(9):827-33. PubMed ID: 26087772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.